OGI Stock Overview
Through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. More details
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Organigram Holdings Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$1.52 |
52 Week High | CA$2.91 |
52 Week Low | CA$1.20 |
Beta | 1.13 |
11 Month Change | -17.84% |
3 Month Change | -23.62% |
1 Year Change | 17.83% |
33 Year Change | -82.41% |
5 Year Change | -85.87% |
Change since IPO | -82.34% |
Recent News & Updates
Organigram: Why I Still Like It
Sep 15Organigram: Q3 2024 Earnings Show Improvement In Revenues And Net Income (Hold)
Aug 14Organigram Has Declined A Lot And Is A Great Deal
Jun 23Recent updates
Organigram: Why I Still Like It
Sep 15Organigram: Q3 2024 Earnings Show Improvement In Revenues And Net Income (Hold)
Aug 14Organigram Has Declined A Lot And Is A Great Deal
Jun 23Organigram: Operating In A Structurally Challenged Industry
Apr 20Don't Rule Out A Bull Market (Podcast Transcript)
Aug 02Don't Rule Out A Bull Market
Jul 27Organigram revenue of $38.12M beats by $12.05M, sees Q4 revenue higher than Q3
Jul 14OrganiGram: Canadian Cannabis Remains Tough To Own
Apr 26Why OrganiGram Should Generate Consistent Growth Going Forward
Jan 16OrganiGram: Positive Signs, But Struggles Persist
Jul 14OrganiGram Holdings (OGI) Investor Presentation - Slideshow
Jun 16Organigram CEO Greg Engel to step down
May 03OrganiGram: The Hype Is Over
Apr 27Organigram EPS misses by $0.14, beats on revenue
Jan 12Shareholder Returns
OGI | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 5.6% | 1.6% | 2.2% |
1Y | 17.8% | 9.9% | 31.6% |
Return vs Industry: OGI exceeded the US Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: OGI underperformed the US Market which returned 31.6% over the past year.
Price Volatility
OGI volatility | |
---|---|
OGI Average Weekly Movement | 6.2% |
Pharmaceuticals Industry Average Movement | 9.5% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OGI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: OGI's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 984 | Beena Goldenberg | www.organigram.ca |
Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O’ Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis.
Organigram Holdings Inc. Fundamentals Summary
OGI fundamental statistics | |
---|---|
Market cap | US$167.02m |
Earnings (TTM) | -US$164.18m |
Revenue (TTM) | US$106.75m |
1.6x
P/S Ratio-1.0x
P/E RatioIs OGI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
OGI income statement (TTM) | |
---|---|
Revenue | CA$149.21m |
Cost of Revenue | CA$114.13m |
Gross Profit | CA$35.07m |
Other Expenses | CA$264.55m |
Earnings | -CA$229.48m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.11 |
Gross Margin | 23.51% |
Net Profit Margin | -153.80% |
Debt/Equity Ratio | 0.06% |
How did OGI perform over the long term?
See historical performance and comparison